Calithera to Present at the H.C. Wainwright 24th Annual Global Investment Conference
SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the companys founder, president and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14 both virtually and in New York, NY.
- SOUTH SAN FRANCISCO, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage, precision oncology biopharmaceutical company, today announced that Susan Molineaux, Ph.D., the companys founder, president and chief executive officer, will present at the H.C. Wainwright 24th Annual Global Investment Conference, being held September 12-14 both virtually and in New York, NY.
- The replay of the webcast will be available on the Companys website for 30 days.
- Calithera Biosciences is a clinical-stage, precision oncology biopharmaceutical company developing targeted therapies to redefine treatment for biomarker-specific patient populations.
- The potential product candidates that Calithera develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all.